Your browser doesn't support javascript.
loading
Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.
Kunjachan, Sijumon; Kotb, Shady; Pola, Robert; Pechar, Michal; Kumar, Rajiv; Singh, Bijay; Gremse, Felix; Taleeli, Reza; Trichard, Florian; Motto-Ros, Vincent; Sancey, Lucie; Detappe, Alexandre; Yasmin-Karim, Sayeda; Protti, Andrea; Shanmugam, Ilanchezhian; Ireland, Thomas; Etrych, Tomas; Sridhar, Srinivas; Tillement, Olivier; Makrigiorgos, Mike; Berbeco, Ross I.
Affiliation
  • Kunjachan S; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. sijumon@gmail.com.
  • Kotb S; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Pola R; Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.
  • Pechar M; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.
  • Kumar R; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.
  • Singh B; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Gremse F; Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.
  • Taleeli R; Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.
  • Trichard F; Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.
  • Motto-Ros V; Division of Medical Physics & Engineering, University of Texas Southwestern Medical Center, Texas, United States.
  • Sancey L; Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.
  • Detappe A; Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.
  • Yasmin-Karim S; Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR 5309 Joint Research Center, Grenoble, France.
  • Protti A; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Shanmugam I; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Ireland T; Lurie Family Imaging Center, Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Etrych T; Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.
  • Sridhar S; LA-ICP-MS and ICP-ES Laboratories, Department of Earth and Environmental Sciences, Boston University, Boston, MA, United States.
  • Tillement O; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.
  • Makrigiorgos M; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Berbeco RI; Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.
Sci Rep ; 9(1): 15844, 2019 11 01.
Article in En | MEDLINE | ID: mdl-31676822
Effective drug delivery is restricted by pathophysiological barriers in solid tumors. In human pancreatic adenocarcinoma, poorly-permeable blood vessels limit the intratumoral permeation and penetration of chemo or nanotherapeutic drugs. New and clinically viable strategies are urgently sought to breach the neoplastic barriers that prevent effective drug delivery. Here, we present an original idea to boost drug delivery by selectively knocking down the tumor vascular barrier in a human pancreatic cancer model. Clinical radiation activates the tumor endothelial-targeted gold nanoparticles to induce a physical vascular damage due to the high photoelectric interactions. Active modulation of these tumor neovessels lead to distinct changes in tumor vascular permeability. Noninvasive MRI and fluorescence studies, using a short-circulating nanocarrier with MR-sensitive gadolinium and a long-circulating nanocarrier with fluorescence-sensitive nearinfrared dye, demonstrate more than two-fold increase in nanodrug delivery, post tumor vascular modulation. Functional changes in altered tumor blood vessels and its downstream parameters, particularly, changes in Ktrans (permeability), Kep (flux rate), and Ve (extracellular interstitial volume), reflect changes that relate to augmented drug delivery. The proposed dual-targeted therapy effectively invades the tumor vascular barrier and improve nanodrug delivery in a human pancreatic tumor model and it may also be applied to other nonresectable, intransigent tumors that barely respond to standard drug therapies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Delivery Systems / Magnetic Resonance Angiography / Metal Nanoparticles / Human Umbilical Vein Endothelial Cells / Optical Imaging / Gold / Neoplasms, Experimental / Neovascularization, Pathologic Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Delivery Systems / Magnetic Resonance Angiography / Metal Nanoparticles / Human Umbilical Vein Endothelial Cells / Optical Imaging / Gold / Neoplasms, Experimental / Neovascularization, Pathologic Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom